Overview

Efficacy and Safety of SPARC0921 in Subjects With Spasticity

Status:
Completed
Trial end date:
2017-08-25
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess whether SPARC0921 demonstrate efficacy and safety in the treatment of spasticity.
Phase:
Phase 3
Details
Lead Sponsor:
Sun Pharma Advanced Research Company Limited